For Licensed Healthcare Practitioners
Peptides & Your Practice
Know More. Decide with Confidence.
Whether you're evaluating peptide therapy for the first time or expanding an existing program, ReViaWell helps practitioners understand the science, evaluate manufacturing quality, navigate today's regulatory landscape, and build peptide programs with confidence.
Evaluate
Decide
Verify
Implement
Grow
A brief conversation. No obligation. No minimum order.
Manufacturing
U.S. FDA-registered manufacturing facilities
Domestic manufacturing; not represented as a 503A pharmacy or 503B outsourcing facility.
Quality Systems
cGMP and ISO registered and compliant
Manufacturing follows documented quality systems, controls, procedures, and standards.
Independent Testing
Documented and independently verifiable
Identity, purity, stability, residuals and fillers, heavy metals, endotoxins, and other applicable quality attributes.
Documentation
Batch-specific records and third-party COAs
Documentation designed to help practitioners evaluate source, quality, and consistency.
U.S. Manufactured
FDA-Registered Facilities
cGMP · ISO
Identity & Purity Verified
Metals & Endotoxin Testing
Batch Documentation
Why practitioners choose Revia Well
Peptides are here.
Is your practice ready?
The question is no longer whether patients will ask about peptides. The question is whether your practice is prepared to evaluate them, discuss them responsibly, and identify supply you can document.
01
Supply chain uncertainty
Peptide Sciences shut down in March 2026. Warning letters hit a dozen more vendors. The gray market suppliers your patients relied on are disappearing. A reliable, quality-documented source isn't optional — it's urgent.
→ Revia Well is a US-sourced, fully documented supply chain that's still standing.
02
Defensibility
If your state board, malpractice carrier, or a patient attorney asked today to document your peptide supplier — the manufacturer, the testing methodology, the batch records — what would you hand them? Most practitioners have no answer.
→ Every Revia Well order includes a clinic-ready compliance documentation pack.
03
The transition
FDA review, compounding policy, approved-drug availability, and state practice rules continue to evolve. Practitioners need current information rather than assumptions or social-media summaries.
→ ReViaWell tracks the landscape and helps you understand what has changed, what has not, and what it may mean for your practice.
Testing protocol
What we test on every batch.
Independent third-party laboratory testing on every production batch — not sampled, not estimated. Batch-specific certificates of analysis available for your clinic records.
Method: RP-HPLC
Purity
≥98% minimum — confirmed
Reverse-phase high-performance liquid chromatography. Gold standard for peptide purity quantification. Distinguishes the target compound from synthesis byproducts and degradation products.
Method: LC-MS
Identity
Compound confirmed — every batch
Liquid chromatography–mass spectrometry confirms molecular identity at the sequence level. Verifies the exact compound — not just a purity percentage — before the batch ships.
Method: ICP-MS
Heavy Metals
<50 ppb — all metals
Inductively coupled plasma–mass spectrometry. Tests for lead, arsenic, mercury, and cadmium. Most gray market vendors never run this panel. It is non-negotiable for any injectable-grade compound.
Documented
Stability
Degradation profile on file
Stability data documents compound integrity over time and temperature exposure. Essential for clinic storage protocols and patient counseling on shelf life.
On our COA documentation: Testing is conducted by Chromate Independent Laboratory (chromate.org/verify), a third-party analytical laboratory independent of Revia LLC and our manufacturing partner. Every COA includes a batch number, access code, and independent verification link. Batch-specific COAs are provided with every practitioner order and are formatted for clinic compliance files.
Regulatory context
The honest timeline to
503A compounding access.
The regulatory picture is moving — but slower than the headlines suggest. Here's what's actually happening and what it means for your practice.
Apr 22, 2026
12 peptides removed from FDA Category 2 Complete
Including BPC-157, TB-500, GHK-Cu, Semax, Epitalon, KPV, MOTS-C, LL-37, and more. Removal from Category 2 does not authorize compounding — it removes the prohibition.
Jul 23–24, 2026
PCAC advisory committee review — 7 peptides Completed
BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and Emideltide were reviewed for possible inclusion on the 503A Bulks List. Committee recommendations are advisory and non-binding; FDA action and any required rulemaking remain pending.
Before Feb 2027
Additional PCAC review — 5 peptides Pending
FDA has announced a future PCAC review for GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II. The meeting is expected before the end of February 2027.
Late 2027 est.
FDA decision and any rulemaking Pending
Notice-and-comment rulemaking typically takes 12–18 months after a favorable PCAC vote. Based on historical FDA rulemaking timelines, late 2027 is the optimistic estimate.
Revia LLC on the federal record
Revia LLC submitted formal public comments to the FDA's Pharmacy Compounding Advisory Committee on June 10, 2026, in support of 503A inclusion for all 12 peptides under review. Comment tracking number: mq8-c88x-9wb1. Docket: FDA-2025-N-6895. View on regulations.gov →
Practitioner account benefits
What every practitioner
account includes.
Approved accounts receive practitioner pricing, full documentation, and ongoing regulatory support — with no minimum order requirement to get started.
Practitioner pricing
Per-unit practitioner pricing exclusive to qualified practitioners. Pricing provided upon practitioner review. No minimum order — trial orders welcome.
Compliance documentation pack
Batch-specific COAs for every compound ordered, manufacturer credentials, testing methodology documentation, and regulatory status summary — formatted for clinic files.
Autoship available
Set recurring orders for your most-used compounds. Predictable supply for active clinic accounts with no disruption to patient protocols.
Regulatory briefings
Direct updates on PCAC hearing outcomes, rulemaking timelines, and what each regulatory development means for your practice — before it hits the general media.
Protocol resources
Access to clinical protocol resources via Peptide Protocol Portal and Integrative Practice Solutions to support your patient programs.
Transition support
When 503A compounding pharmacy access opens, we'll help you transition. You won't need to quietly walk away from a gray market vendor — we're already building toward that standard.
Available compounds
Compounds available to
practitioner accounts.
A practical reference to the compounds practitioners are hearing about, how they are structured, why they are being discussed, and where they currently stand with the FDA.
| Category | Compound | Compound Structure | Area of Interest | Current U.S. Regulatory Status |
|---|---|---|---|---|
| Metabolic | Semaglutide | GLP-1 receptor agonist | Weight management; glucose regulation | FDA-approved drug ingredient for specific indications; FDA proposed exclusion from the 503B Bulks List. |
| Metabolic | Tirzepatide | Dual GIP/GLP-1 receptor agonist | Weight management; glucose regulation | FDA-approved drug ingredient for specific indications; FDA proposed exclusion from the 503B Bulks List. |
| Metabolic | Retatrutide | Triple GIP/GLP-1/glucagon receptor agonist | Weight management; metabolic health | Investigational; not FDA-approved. |
| Metabolic | Cagrilintide | Long-acting amylin analogue | Appetite regulation; weight management | Investigational; not FDA-approved. |
| Metabolic | Mazdutide | Dual GLP-1/glucagon receptor agonist | Weight management; metabolic health | Investigational in the U.S.; not FDA-approved. |
| Metabolic | Survodutide | Dual GLP-1/glucagon receptor agonist | Weight management; liver and metabolic health | Investigational; not FDA-approved. |
| Metabolic | 5-Amino-1MQ | Small-molecule NNMT inhibitor | Body composition; metabolic research | Investigational/research; not FDA-approved. |
| Metabolic | AOD-9604 | Modified hGH fragment | Fat-metabolism research | Not FDA-approved; FDA identifies potential safety and characterization concerns for compounded products. |
| Recovery | BPC-157 | Synthetic gastric pentadecapeptide | Tissue, gastrointestinal, and recovery research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Recovery | TB-500 | Thymosin beta-4-related peptide fragment | Wound and musculoskeletal recovery research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Recovery | KPV | α-MSH-derived tripeptide | Inflammatory pathways; skin and gastrointestinal research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Recovery | GHK-Cu | Copper-binding tripeptide | Skin, hair, tissue, and wound-healing research | Not FDA-approved as a peptide drug; announced for future PCAC 503A review before the end of February 2027. |
| Recovery | LL-37 | Human cathelicidin antimicrobial peptide | Innate immunity and wound research | Not FDA-approved; announced for future PCAC 503A review before the end of February 2027. |
| Recovery | Carnosine | Naturally occurring dipeptide | Cellular protection and recovery research | Not FDA-approved as a peptide drug for these uses. |
| Growth Hormone | CJC-1295 (No DAC) | GHRH analogue | Growth-hormone signaling and body-composition research | Not FDA-approved. |
| Growth Hormone | CJC-1295 (DAC) | Long-acting GHRH analogue | Extended growth-hormone signaling research | Not FDA-approved. |
| Growth Hormone | Ipamorelin | Ghrelin-receptor agonist / GH secretagogue | Growth-hormone release and body-composition research | Not FDA-approved; 503A nomination reviewed by PCAC in 2024; FDA action pending. |
| Growth Hormone | Sermorelin | GHRH(1-29) analogue | Pituitary growth-hormone stimulation | Not currently marketed as an FDA-approved drug product; regulatory and compounding considerations apply. |
| Growth Hormone | Tesamorelin | Stabilized GHRH analogue | Visceral adipose tissue reduction | FDA-approved prescription drug for a specific indication. |
| Growth Hormone | Hexarelin | Ghrelin-receptor agonist / GH secretagogue | Growth-hormone release research | Not FDA-approved. |
| Growth Hormone | PEG-MGF | Pegylated IGF-1 splice-variant peptide | Muscle and tissue research | Not FDA-approved; announced for future PCAC 503A review before the end of February 2027. |
| Longevity | MOTS-c | Mitochondrial-derived peptide | Metabolic signaling; obesity and bone research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Longevity | SS-31 (Elamipretide) | Mitochondria-targeting tetrapeptide | Mitochondrial function and cellular-energy research | Investigational; not FDA-approved. |
| Longevity | Epitalon | Synthetic tetrapeptide | Sleep and healthy-aging research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Longevity | Humanin | Mitochondrial-derived peptide | Cellular resilience and metabolic research | Investigational/research; not FDA-approved. |
| Longevity | FOXO4-DRI | D-retro-inverso peptide | Cellular-senescence research | Preclinical/research; not FDA-approved. |
| Cognitive | Semax | ACTH-derived heptapeptide | Cognition and neurologic research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Cognitive | Selank | Tuftsin-derived heptapeptide | Stress, anxiety, and cognition research | Not FDA-approved; FDA identifies potential safety and characterization concerns for compounded products. |
| Cognitive | Dihexa | Angiotensin IV-derived peptide analogue | Neuroplasticity and cognitive research | Not FDA-approved; announced for future PCAC 503A review before the end of February 2027. |
| Cognitive | Emideltide (DSIP) | Delta sleep-inducing peptide | Sleep and neurologic research | Not FDA-approved; PCAC review completed July 2026 for possible 503A Bulks List inclusion; FDA action pending. |
| Aesthetics & Wellness | PT-141 (Bremelanotide) | Melanocortin receptor agonist | Sexual-health research | Bremelanotide is FDA-approved for a specific indication; other uses are not approved. |
| Aesthetics & Wellness | Afamelanotide (Melanotan I) | α-MSH analogue / melanocortin agonist | Pigmentation and photoprotection | Afamelanotide is FDA-approved for a specific indication; informal products sold as “Melanotan I” may not be equivalent. |
| Aesthetics & Wellness | Melanotan II | Synthetic melanocortin agonist | Pigmentation and sexual-function research | Not FDA-approved; announced for future PCAC 503A review and identified by FDA as presenting potential safety risks in compounding. |
Regulatory status is descriptive, not a legal conclusion. FDA approval applies to the approved drug product, indication, formulation, and conditions of use. PCAC recommendations are advisory and do not themselves authorize compounding. Statuses should be reviewed periodically as FDA policy and rulemaking evolve.
On the federal record
We submitted formal FDA public comments.
Revia LLC submitted written comments to the FDA's Pharmacy Compounding Advisory Committee on June 10, 2026, in support of 503A inclusion for BPC-157, TB-500, Semax, Epitalon, KPV, MOTS-C, Emideltide, and the five compounds scheduled for February 2027 review. We argued that quality-documented US suppliers deserve a regulated pathway — and that the gray market restriction created the unsafe supply chain it was meant to prevent.
Tracking: mq8-c88x-9wb1 · Docket: FDA-2025-N-6895 · Document: FDA-2025-N-6895-0001
Federal record
Practitioner conversation
Are peptides right for your practice?
Let’s have a qualified conversation. Tell us who you are and what you are exploring. We will respond within one business day.
Thank you.
We received your information and will contact you within one business day. For an immediate question, email contact@revialife.com.